A group of institutional investors renewed its push for a shakeup in Mylan’s boardroom Thursday, calling for the resignation of chairman Robert Coury and director Wendy Cameron in addition to other measures it said were needed to restore investor confidence and independent oversight on behalf of shareholders.

The effort followed release of the final vote tally from the generic drug giant’s annual meeting last week that revealed a high level of shareholder discontent with the board and how much the company pays its top executives.

Calling the results a “vote of no confidence in Mylan’s entire board,” the group, led by New York City comptroller Scott Stringer, wrote a letter to independent directors urging them to “act swiftly — or risk further erosion in shareholder confidence and value.”

“Mylan’s share price is already down nearly 50 percent since its April 2015 peak and the company remains under legal, regulatory and public scrutiny for its EpiPen [allergy shot] pricing practices,” the letter said.

Advertise with us

Voting results, released in a filing with the U.S. Securities and Exchange Commission Wednesday evening, showed shareholders rejected the company’s executive pay practices by an overwhelming 84 percent of votes cast. It also showed weak support for a number of Mylan’s long-time directors.

Ms. Cameron — co-owner of a harness racing business in Washington, Pa., who has been on Mylan’s board since 2002 — faced the most opposition, with 56 percent of shares voted cast against her re-election. Chair of the compensation committee, she was the only director to receive more nay votes than yay, but others came close.

Neil Dimick and Mark Parrish, the other members of the compensation committee, had 50 percent and 48 percent of shares voted cast against them, respectively.

Mr. Coury, whose nearly $100 million compensation package in 2016 fueled the most recent protests, had 34 percent “no” votes, while 27 percent voted against CEO Heather Bresch.

Mylan last week announced that all 10 incumbent directors and one new nominee had been elected to the board and that shareholders had rejected its pay practices, but did not release percentages or the exact vote tallies.

Advertise with us

Under Mylan’s rules, nominees can be elected with as little as 34 percent of the votes cast.

Mr. Stringer’s group — which includes the New York City and New York State pension funds and the California State Teachers’ Retirement System — called those election rules “obscure” and “untenable.”

“Requiring two-thirds of votes cast to remove a director, is ultimately untenable, for both the board and directors,” the group said in its letter. About 90 percent of companies in the Standard and Poor’s 500 have majority voting policies in place, the letter said.

Mylan did not respond to emails Thursday seeking comment.

In the SEC filing, the board said it “respectfully acknowledges” the voting results, and would “engage in an extensive program of shareholder outreach over the coming months in order to elicit and understand the perspectives of Mylan’s shareholders.”

Advertise with us

Rosanna Landis Weaver, program manager at the shareholder advocacy foundation As You Sow, said shareholders spoke loudly and clearly in the non-binding say-on-pay vote.

“If a company gets 83.5 percent in favor it is considered a weak level of support. [To get] 83.5 percent against is just unheard of,” she said in an email. “It is an astonishing rebuke, and one hopes that Mylan’s board will listen.”

Since 2011, public companies have been required to hold advisory votes allowing shareholders to voice their approval or disapproval of executive compensation. Mylan shareholders also rejected the company’s pay practices in 2012.

So far this year, just 1 percent of plans have been voted down, according to compensation consultant Semler Brossy.

Mr. Stringer’s group, along with three prominent proxy advisory firms, had mounted a campaign urging Mylan shareholders to oust some or all of the company’s directors at the annual meeting, citing a track record of excessive executive pay and poor oversight by the board.

Advertise with us

Besides prompt removal of Ms. Cameron and Mr. Coury, the pension fund group Thursday offered a list of recommended actions, such as reconstituting the board with a majority of “new, diverse and genuinely independent directors,” hiring an independent compensation consultant, and requiring that the chairman of the board be an independent director.

The letter also called on Mylan to disclose any actions to enhance the company’s internal controls and compliance in the wake of the outcry and accusations of price-gouging over the 500 percent increase in the price of the EpiPen. And it wants Mylan to disclose actions to “hold accountable any current or former Mylan employee, including a senior executive, who either committed misconduct or failed in his or her responsibilities to manage or monitor any related conduct and risks.”

Mylan’s shares lost 31 cents Thursday, or 0.8 percent, to close at $38.76.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.